One of the questions we keep being asked is whether a comprehensive IR strategy truly impacts share price performance. After all, many companies argue that if we run our business well, the share price will take care of itself. Like… Read More »Mind the gap! How a comprehensive IR strategy leads to outperformance
Much has been said about the implications of MiFID II on stock research coverage levels (see our earlier blogpost and analysis) and the economics of sell side brokerage, but the elephant in the room is what this means for access… Read More »Investor Targeting – Things ain’t what they used to be…
Shareholder identification is crucial for listed companies as it enables effective engagement with their current investor base, but historically often commanded limited attention due to the difficulty of the ID process, with corporates having relatively limited access to information outside of very… Read More »Cracking the Shareholder Code: SRD II’s European Revolution
Clearharts analysis of post IPO performance data underlines the importance for your share price of getting your IR strategy right in the first 6-9 months of being listed. We had a lot of questions about last weeks blog post where… Read More »Your IPO is just the beginning of the story – part 2
Here at Clearhart we know that IR strategy in and around IPO is vitally important to the future performance of your share price. IPOs are a defining event in the lifecycle of a company, often seen as a stamp of approval,… Read More »Your IPO is just the beginning of the story – part 1
Capital Markets Days (CMDs) are pivotal for investor relations, and our proprietary analysis provides compelling evidence of their effectiveness. We show that CMDs can significantly boost trading volumes, generating a substantial impact on market activity. Capital Markets Days, or CMDs, are the flagship events of any… Read More »Boost your trading volumes with a CMD
Last week, we talked about the potential changes to MiFID II rules that have led to significantly reduced sell-side coverage by brokers and independent research firms since its 2018 implementation. Sell-side coverage is vital for corporates as it stimulates investor… Read More »The small cap effect
There has been a lot of commentary this week on the proposed removal of the much maligned MIFID II rules, but sadly you can’t unscramble an egg. The elephant in the room is that by destroying the economics of research… Read More »Mifid II reversal won’t solve the lack of coverage problem for European small caps